Ranbaxy Of India Said Set To Acquire India's Biovel For $110 MIllion
This article was originally published in PharmAsia News
Executive Summary
India's Ranbaxy Laboratories reportedly is negotiating a takeover of Biovel Life Sciences, an India-based biotech. The acquisition price is estimated at $110 million. Sources say the takeover is expected to occur soon, but neither company would comment. The proposed acquisition is expected to give Ranbaxy expanded opportunities in biotechnology drugs. (Click here for more